Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.906 -0.024 (-0.34%)
Streaming Delayed Price Updated: 9:45 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,974,475
Open 6.950
Bid (Size) 6.900 (500)
Ask (Size) 6.910 (200)
Prev. Close 6.930
Today's Range 6.760 - 7.100
52wk Range 1.830 - 8.280
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)
Via AB Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
+241.9%
+241.9%
1 Month
+166.7%
+166.7%
3 Month
+219.7%
+219.7%
6 Month
+179.6%
+179.6%
1 Year
+103.7%
+103.7%

More News

Read More
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs ↗
Via Stocktwits
News headline image
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
From ImmunityBio
Via Business Wire
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
Via The Motley Fool
Topics Stocks
News headline image
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗
Via Stocktwits
Topics Death ETFs
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
Via AB Newswire
News headline image
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗
Via The Motley Fool
Topics Stocks
News headline image
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗
Via Stocktwits
Topics Death
News headline image
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
From ImmunityBio, Inc.
Via Business Wire
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
Via The Motley Fool
Topics Stocks
News headline image
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
Via The Motley Fool
Topics Stocks
Which stocks are most active on Tuesday? ↗
Via Chartmill
News headline image
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗
Via Stocktwits
Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year ↗
Via The Motley Fool
Topics Stocks
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Skyrocketing Again Today ↗
Via The Motley Fool
Curious about the most active stocks on Friday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 6.906
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 02/10/26 09:45 AM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 2.70B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS